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Correction
After the publication of this research article [1], the
authors noticed an error with Figure 1. Graph D which
should have indicated miR-106b expression levels in
renal parenchyma (RP) and renal cell carcinomas (RCC),
was mistakenly displayed as a duplicate of Graph C. The
corrected Figure 1 is provided here.
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